ERBB2 and breast carcinoma: These results are of imperative significance because it suggests the preferred sensitivity of ErbB2-overexpressing cancer cells to ganetespib, which provides key preclinical evidence that supports the rationale for the application of ganetespib in ErbB2+ breast cancer.